Hypoparathyroidism Treatment Market: Adoption of Fast Track Drug Approval Status by Pivotal Regulatory Bodies and Significant Unmet Needs for Medicines to Create Lucrative Revenue Opportunities: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2026

  • Published: 2018-12-04
  • Report Code: REP-GB-7857
  1. Home
  2. Syndicated Research

  3. Hypoparathyroidism Treatment Market Opportunity Assessment

An Incisive, In-depth Analysis on the Hypoparathyroidism Treatment Market

This study offers a comprehensive, 360 degree analysis on the Hypoparathyroidism Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Hypoparathyroidism Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Request a sample
Ask An Analyst
Request Special Price
Request Methodology

50% of the Revenue Contribution by the Leading Players

The hypoparathyroidism treatment market is largely dominated by the major players, who are competing on the basis of market penetration and distribution. The consolidated nature of the hypoparathyroidism treatment market increases the profitability. Factors such as poor efficacy and efficiency of the treatment are hampering the adoption of hypoparathyroidism treatment. However, the growing awareness regarding hypoparathyroidism treatmentand number of thyroid surgeries are expected to create growth opportunities for the manufacturers operating in the global hypoparathyroidism treatment market. Shire-NPS Pharmaceuticals, Inc., EnteraBio Ltd., and Teva Pharmaceutical Industries Ltd. hold more than 50% revenue share in the global hypoparathyroidism treatment market. The growth of the global hypoparathyroidism treatment market is primarily driven by growing prevalence of hypoparathyroidism and increasing number of thoracic surgeries and incidence of cancer. Thedevelopment of healthcare infrastructure across the globe coupled with governmental support for hypoparathyroidism treatment is expected to drive the growth of the hypoparathyroidism treatment market. The companies operating in the market are involved in developing new experimental hypoparathyroidism treatment drugs.

Increasing Number of Thoracic Surgeries and Incidence of Cancer

The growing screening rates, increasing number of thoracic surgeries and incidence of cancer are expected to be the prime factors driving the growth of the hypoparathyroidism treatment market. Thyroid or neck surgery is associated with hypoparathyroidism, owing to damage to the parathyroid glands. The number of thyroidectomies in the U.S. reflects 39% increase from 2007 to 2015. This indicates transient post-surgical hypoparathyroidism, which can become permanent in about 25% of cases. The growing incidence of head & neck and thyroid cancers is the other factor expected to drive the growth of the market.

Increasing investments in the research and development coupled with the development of biologics is expected to generate momentum and growth opportunities for the hypoparathyroidism treatment market.

New Drug Development and Government Support to Root Out Hypoparathyroidism

New drug development is expected to create enormous growth opportunity for the hypoparathyroidism treatment market. Any new curative hypoparathyroidism treatment drug is expected to witness fast adoption with minimal resources due to lack of competition in the hypoparathyroidism treatment market. Symptomatic treatment is the chief goal of hypoparathyroidism treatment as there is no treatment for hypoparathyroidism.

The support to hypoparathyroidism treatment products and initiatives by the governments of different countries such as financial incentives and orphan status are the other factors expected to boost the growth of the hypoparathyroidism treatment market. The demographic drivers of the hypoparathyroidism treatment market include growing geriatric population and healthcare expenditure across the globe.

Growing Purchasing Power and Attractive Reimbursements

In the North America hypoparathyroidism treatment market, the U.S. is expected to be the dominant country as it is a large economy and with high purchasing power. Besides, favorable reimbursements for hypoparathyroidism treatment is also expected to support the growth of the hypoparathyroidism market. Likewise, large presence of major players such as Shire-NPS Pharmaceuticals, Inc., and EnteraBio Ltd., among others, is also expected to drive the growth of the hypoparathyroidism treatment market in the U.S. The healthcare expenditure in the U.S. was almost 16% of its GDP in 2017, which reflects better pricing and market attractiveness for the hypoparathyroidism treatment market.

Orphan Status and Incentives

The U.S. FDA’s orphan status to drugs and biologics that affect less than 200,000 people in the U.S. confer various incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval. In the hypoparathyroidism treatment market, Natpara is an approved drug with a black box warning notified by the U.S. FDA in January 2015 – enjoying an exclusivity period till 2022.

Competitive Landscape

This section of the report features the profiles of the key players in the hypoparathyroidism treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. The key players operating in the hypoparathyroidism treatment market include Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and EnteraBio Ltd.

Definition

Hypoparathyroidism is the decreased secretion or activity of parathyroid hormone (PTH) resulting in low blood levels of calcium and higher levels of blood phosphorus

About the Report

FMI conducted a research study on hypoparathyroidism treatment market for the forecast period 2018 to 2022. The hypoparathyroidism treatment market report offers a comprehensive evaluation of the business opportunities prevailing in the hypoparathyroidism treatment market along with insights on the hypoparathyroidism treatment consumption trend, disease incidences, and awareness level for hypoparathyroidism treatment market competition. The report elaborates the macroeconomic factors influencing the dynamics of hypoparathyroidism treatment market and its futuristic potential.

Segmentation

The report offers a comprehensive taxonomy of hypoparathyroidism treatment market based on drug class, route of administration, distribution channels and region. The drug class segment of the hypoparathyroidism treatment market includes parathyroid hormone, vitamin D analogue and calcium supplements. The route of administration segment of the hypoparathyroidism treatment market includes oral, and parenteral. The distribution channel segment of the hypoparathyroidism treatment market includes retail pharmacy, hospital pharmacy and online sales.

The hypoparathyroidism treatment market has been analyzed across regions of North America, Latin America, Europe, Asia Pacific and MEA.

Additional Questions Answered

Some of the additional questions addressed in this report on hypoparathyroidism treatment market-

  • What is the revenue potential of the hypoparathyroidism treatment market across regions of North America and Europe?

  • Who are the key competitors and what are their portfolios in hypoparathyroidism treatment market?

  • What are major challenges influencing the growth of hypoparathyroidism treatment market?

  • How intervention from regulatory authority is shaping the hypoparathyroidism treatment market growth?

Research Methodology

The hypoparathyroidism treatment market has been estimated based on supply-demand approach. The market was first calculated based on incidence and diagnosis rate, conducted in different region/countries. Other qualitative factors analyzed during the estimation include treatment rates for hypoparathyroidism treatment, recurrence rate and others. This information is further validated with rigorous primary research (including in-person interactions, interviews, surveys and viewpoints of seasoned analysts) and secondary research (including resourceful databases, verified paid sources, and authentic trade journals). The research study on hypoparathyroidism treatment market also includes top trends and macro as well as micro economic factors shaping the hypoparathyroidism treatment market. With this approach, the report on hypoparathyroidism treatment market anticipates the industry attractiveness of every major segment in hypoparathyroidism treatment over the forecast period.

A recent market study published by FMI “Hypoparathyroidism Treatment Market: Global Industry Analysis 2013–2017 & Opportunity Assessment 2018–2026” consists a comprehensive assessment of the most important market dynamics. On conducting a thorough research on the historic as well as current growth parameters of the hypoparathyroidism treatment market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may have a huge impact on the development of the hypoparathyroidism treatment market during the forecast period. It can help the players to modify their manufacturing and marketing strategies to envisage maximum growth in the hypoparathyroidism treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects of the hypoparathyroidism treatment market in the most comprehensive way for the better understanding of readers.

Chapter 1 – Executive Summary

The report commences with the executive summary of the hypoparathyroidism treatment market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the hypoparathyroidism treatment market.

Chapter 2 – Market Overview

Readers can find detailed taxonomy and the definition of the hypoparathyroidism treatment market in this chapter, which will help readers to understand the basic information about the hypoparathyroidism treatment market dynamics, supply chain, cost structure, pricing analysis, list of key distributor and suppliers, list of key market participants included in the report.

Chapter 3 – Global Hypoparathyroidism Treatment Market Analysis (2013–2017) & Opportunity Assessment (2018–2026), By Drug Class

Based on the drug class, the hypoparathyroidism treatment market is segmented into parathyroid hormone, vitamin D analogue and calcium supplements. In this chapter, readers can find information about key trends and developments in the hypoparathyroidism treatment market and market attractive analysis based on the drugs, patches and steroid injectable. In this chapter, readers can find information about key trends and developments in the hypoparathyroidism treatment market and market attractive analysis based on the drug class for each region.

Chapter 4 – Global Hypoparathyroidism Treatment Market Analysis (2013–2017) & Opportunity Assessment (2018–2026), By Route of Administration

Based on the route of administration, the hypoparathyroidism treatment market is segmented into oral, and parenteral. In this chapter, readers can find information about key trends and developments in the hypoparathyroidism treatment market and market attractive analysis based on route of administration for each region.

Chapter 5 – Global Hypoparathyroidism Treatment Market Analysis (2013–2017) & Opportunity Assessment (2018–2026), By Distribution Channels

Based on the distribution channels, the hypoparathyroidism treatment market is segmented into retail pharmacy, hospital pharmacy and online sales. In this chapter, readers can find information about key trends and developments in the hypoparathyroidism treatment market and market attractive analysis based on distribution channels for each region.

Chapter 6 – Global Hypoparathyroidism Treatment Market Analysis (2013–2017) & Opportunity Assessment (2018–2026), By Region

This chapter explains how the hypoparathyroidism treatment market will grow across various geographic regions, such as North America, Latin America, Europe, Asia-Pacific, China and the Middle East & Africa (MEA).

Chapter 7 – North America Hypoparathyroidism Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2026

This chapter includes detailed analysis of the growth of the North America hypoparathyroidism treatment market along with the country-wise assessment including the U.S. and Canada. Readers can also find regional trends, regulations, and market growth based on drug class, route of administration, distribution channel and country of hypoparathyroidism treatment in North America.

Chapter 8 – Latin America Hypoparathyroidism Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2026

Readers can find detailed information about factors such as, pricing analysis, and regional trends that are impacting the growth of the Latin America hypoparathyroidism treatment market. This chapter also includes the growth prospects of the hypoparathyroidism treatment market in leading LATAM countries such as Brazil, Mexico, and Rest of the Latin America.

Chapter 9 – Europe Hypoparathyroidism Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2026

Important growth prospects of the hypoparathyroidism treatment market based on its drug class, route of administration, and distribution channels in several European countries, such as Germany, France, Italy, Spain, the U.K., and Rest of Europe are included in this chapter.

Chapter 10 – APEC Hypoparathyroidism Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2026

China, India, Japan, Australia and New Zealand and rest of Asia Pacific are the leading countries in the APEC region that are the prime subject of assessment to obtain growth prospects of the APEC hypoparathyroidism treatment market in this chapter. Readers can find thorough information about the growth parameters of the APEC hypoparathyroidism treatment market during the period 2018–2026.

Chapter 11 – China Hypoparathyroidism Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2026

Readers can find important factors that can have a huge impact on the growth of the hypoparathyroidism treatment market in China based on the market segmentation, during the forecast period. This chapter provides the overview of regulations, drivers, restraints, and trends in the China hypoparathyroidism treatment market.

Chapter 12 – MEA Hypoparathyroidism Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2026

This chapter provides information on how the hypoparathyroidism treatment market will grow in the major countries in MEA region, such as GCC countries, South Africa, and rest of MEA during the period 2018–2026.

Chapter 13 – Competition Landscape, Company Share and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the hypoparathyroidism treatment market along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Market players featured in the report include Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and EnteraBio Ltd.

Chapter 14 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 15 – Research Methodology

This chapter helps readers to understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the hypoparathyroidism treatment market.

Hypoparathyroidism Treatment Market Reports - Table of Contents

Hypoparathyroidism Treatment Market Reports - List of Tables

  1. Global Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Drug Class

  2. Global Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Route of Administration

  3. Global Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by End-users

  4. Global Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Region

  5. North America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Country

  6. North America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Drug Class

  7. North America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Route of Administration

  8. North America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Distribution Channels

  9. Europe Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Country

  10. Europe Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Drug Class

  11. Europe Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Route of Administration

  12. Europe Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Distribution Channels

  13. Asia Pacific Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Country

  14. Asia Pacific Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Drug Class

  15. Asia Pacific Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Route of Administration

  16. Asia Pacific Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Distribution Channels

  17. Latin America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Country

  18. Latin America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Drug Class

  19. Latin America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Route of Administration

  20. Latin America Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Distribution Channels

  21. MEA Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Country

  22. MEA Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Drug Class

  23. MEA Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Route of Administration

  24. MEA Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, 2016–2026, by Distribution Channels

Hypoparathyroidism Treatment Market Reports - List of Figures

  1. Global America Hypoparathyroidism Treatment Market Value Share By Drug Class (2018 E)

  2. Global America Hypoparathyroidism Treatment Market Value Share By Route of Administration (2018 E)

  3. Global America Hypoparathyroidism Treatment Market Value Share By Distribution Channels (2018 E)

  4. Global America Hypoparathyroidism Treatment Market Value Share By Region  (2018 E)

  5. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Parathyroid Hormone

  6. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Vitamin D Analogue

  7. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Calcium Supplements

  8. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026

  9. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Oral

  10. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Parenteral

  11. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Route of Administration, 2018-206

  12. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Hospital Pharmacy

  13. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Retail Pharmacy

  14. Global Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026, by Online Sales

  15. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Distribution Channels, 2018-2026

  16. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Region, 2018-2026

  17. North America Hypoparathyroidism Treatment Market Value Share By Drug Class (2018 E)

  18. North America Hypoparathyroidism Treatment Market Value Share By Route of Administration (2018 E)

  19. North America Hypoparathyroidism Treatment Market Value Share By Distribution Channels (2018 E)

  20. North America Hypoparathyroidism Treatment Market Value Share By Country  (2018 E)

  21. North America Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026

  22. North America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Country

  23. North America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Drug Class

  24. North America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Route of Adm

  25. North America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Distribution

  26. Europe Hypoparathyroidism Treatment Market Value Share By Drug Class (2018 E)

  27. Europe Hypoparathyroidism Treatment Market Value Share By Route of Administration (2018 E)

  28. Europe Hypoparathyroidism Treatment Market Value Share By Distribution Channels (2018 E)

  29. Europe Hypoparathyroidism Treatment Market Value Share By Region (2018 E)

  30. Europe Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026

  31. Europe Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Country

  32. Europe Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Drug Class

  33. Europe Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Route of Administra

  34. Europe Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Distribution Channe

  35. Asia Pacific Hypoparathyroidism Treatment Market Value Share By Drug Class (2018 E)

  36. Asia Pacific Hypoparathyroidism Treatment Market Value Share By Route of Administration (2018 E)

  37. Asia Pacific Hypoparathyroidism Treatment Market Value Share By Distribution Channels (2018 E)

  38. Asia Pacific Hypoparathyroidism Treatment Market Value Share By Region (2018 E)

  39. Asia Pacific Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026

  40. Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Country

  41. Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Drug Class

  42. Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Route of Admi

  43. Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Distribution

  44. Latin America Hypoparathyroidism Treatment Market Value Share By Drug Class (2018 E)

  45. Latin America Hypoparathyroidism Treatment Market Value Share By Route of Administration (2018 E)

  46. Latin America Hypoparathyroidism Treatment Market Value Share By Distribution Channels (2018 E)

  47. Latin America Hypoparathyroidism Treatment Market Value Share By Region (2018 E)

  48. Latin America Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026

  49. Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Country

  50. Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Drug Class

  51. Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Route of Adm

  52. Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Distribution

  53. MEA Hypoparathyroidism Treatment Market Value Share By Drug Class (2018 E)

  54. MEA Hypoparathyroidism Treatment Market Value Share By Route of Administration (2018 E)

  55. MEA Hypoparathyroidism Treatment Market Value Share By Distribution Channels (2018 E)

  56. MEA Hypoparathyroidism Treatment Market Value Share By Region (2018 E)

  57. MEA Hypoparathyroidism Treatment Market Revenue (US$ Mn), 2016–2026

  58. MEA Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Country

  59. MEA Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Drug Class

  60. MEA Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Route of Administratio

  61. MEA Hypoparathyroidism Treatment Market Attractiveness Analysis (2018-2026), By Distribution Channels

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

+44 (0) 20 3287 4268
Pranay Mhaisekar

Pranay Mhaisekar

Business Development

+ 44 (0) 20 7692 8790
* indicates mandatory fields.

Latest Insights

Our Clients

Press Releases:

Recommendations

CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Learn More
Request Sample Ask An Analyst Request Special Price Request Methodology